Article
Diversity in Cancer Clinical Trials
“I think it’s important to ensure that you consider each person uniquely. Because no matter how much I know or the nurse knows about the population, everybody is a little bit different. It’s really important to personalize every approach and ask them what they know and meet them where they are,” ONS member Reneé Kurz, DNP, RN, FNP-BC, AOCNP®, director of clinical research operations at Rutgers Cancer Institute of New Jersey in New Brunswick, told Jaime Weimer, MSN, RN, AGCNS-BC, AOCNS®, oncology clinical specialist at ONS, during a conversation about increasing diversity in clinical trials.
Related Topics
You May Also Like
Article
Sponsorship of oncology clinical trials in the United States according to age of eligibility
Article
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
Article
Finding the Right Drug at the Right Dose the First Time: Has the Era of Personalized Formularies Finally Arrived?
Article
Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
Article